Nuevo y primer tratamiento aprobado para Cancer de Celulas de Merkel

First Merkel cell carcinoma treatment approved

The U.S. Food and Drug Administration has granted accelerated approval to EMD Serono's Bavencio (avelumab) to treat patients ages 12 and up with metastatic Merkel cell carcinoma, including patients who have not received chemotherapy. The PD-L-1 inhibitor was approved based on data from a single-arm trial of 88 patients with metastatic MCC who had been previously treated with at least one prior chemotherapy regimen, 33 percent of whom experienced complete or partial shrinkage of their tumors. The response lasted for more than six months in 86 percent of responding patients and more than 12 months in 45 percent of responding patients. The treatment can cause a number of side effects, may lead the immune system to attack healthy cells or organs, and carries the risk of infusion-related reactions. 

Biologics and targeted therapies are helping dermatologists treat many skin conditions more effectively than ever before — and more are in the pipeline. Read more about conditions that may see new treatment options in the near future in Dermatology World. 

Benjamin Hidalgo-Matlock

Skin Care Physicians of Costa Rica

4000-1054

2208-8206

Please excuse the shortness of this message, as it has been sent from a mobile device.